FACE-Rare: FACE for Children With Rare Diseases

Sponsor
Children's National Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT04855734
Collaborator
Respecting Choices (Other), National Institutes of Health (NIH) (NIH), National Institute of Nursing Research (NINR) (NIH)
60
1
2
11.8
5.1

Study Details

Study Description

Brief Summary

Children with ultra-rare or complex rare diseases are routinely excluded from research studies because of their conditions, creating a health disparity. However, new statistical techniques make it possible to study small samples of heterogeneous populations. We propose to study the palliative care needs of family caregivers of children with ultra-rare diseases and to pilot test a palliative care needs assessment and advance care planning intervention to facilitate discussions about the future medical care choices families are likely to be asked to make for their child.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: FAmily CEntered (FACE) pACP Intervention
N/A

Detailed Description

A rare disease is a condition affecting fewer than 200,000 persons. Pediatric patients with rare diseases experience high mortality with 30% not living to see their 5th birthday. Families are likely to be asked to make complex medical decisions for their child. Pediatric advance care planning involves preparation and skill development to help make future medical care choices. Children with rare disorders are a heterogeneous group often with co-morbidities, resulting in their exclusion from research, thereby creating a health disparity for this vulnerable population. Available research on families of children with rare diseases lacks scientific rigor. Although desperately needed, there are few empirically validated interventions to address these issues. We propose to close a gap in our knowledge of families' needs for support in a heterogeneous group of children with rare diseases; and to test an advance care planning intervention.

The FAmily CEntered (FACE) pediatric advance care planning intervention, proven successful with cancer and HIV, is adapted to families with children who have rare diseases. Theoretically informed and developed by the PI, Dr. Lyon, and colleagues, the proposed intervention will use Respecting Choices Next Steps Pediatric Advance Care Planning™ for families whose child is unable to participate in health care decision-making. Our consultation with families of children with rare disorders and the National Organization for Rare Disorders (NORD) revealed that basic palliative care needs should be addressed first, before an advance care planning intervention. For the study to be able to meet this request, all families randomized to the intervention will first complete the Carer Support Needs Assessment Tool (CSNAT)© which our investigative team adapted for use in pediatrics. In the CSNAT Approach, facilitators assess caregivers' prioritized palliative care needs and develop Shared Action Plans for palliative care support. Thus, we propose an innovative 3-session FACE-Rare intervention, integrating two evidence-based approaches. We will evaluate FACE-Rare using a scientifically rigorous intent-to-treat, single-blinded, randomized controlled trial design. Family/child pairs or dyads (N=30 dyads) will be randomized to FACE-Rare (CSNAT Sessions 1 & 2 plus Respecting Choices Sessions 3) or control (Treatment As Usual) groups. Both groups will receive palliative care information. All families will complete questionnaires at baseline and 3-months follow-up. Investigators will evaluate the initial efficacy of FACE-Rare on family quality of life (psychological, spiritual). We will estimate how religiousness and caregiver appraisal influence families' quality of life. We will also explore health care utilization by the children during the study and family satisfaction.

If the aims of this pilot trial are achieved, a future, large, multi-site trial will test the full theoretical model to improve care for children with rare diseases and their families through family engaged pediatric Advance Care Planning. The ultimate goal is to minimize suffering and enhance the quality of life of family caregivers of children with rare diseases; and through this process to improve the palliative care of their children.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Investigators propose a pilot, two-arm, intent-to-treat, single-blinded, single-site, controlled RCT. Family/child dyads (N=30) will be enrolled and randomized to either the FACE-Rare intervention or treatment as usual (TAU) at a 1:1 ratio.Investigators propose a pilot, two-arm, intent-to-treat, single-blinded, single-site, controlled RCT. Family/child dyads (N=30) will be enrolled and randomized to either the FACE-Rare intervention or treatment as usual (TAU) at a 1:1 ratio.
Masking:
Single (Outcomes Assessor)
Masking Description:
Study arm allocation will be concealed from the Research Assistant (RA) Assessor to prevent bias during the administration of outcome questionnaires, process measures, and chart abstraction.
Primary Purpose:
Supportive Care
Official Title:
Palliative Care Needs of Children With Rare Diseases and Their Families
Actual Study Start Date :
Jul 6, 2021
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: FACE-Rare Intervention

FACE-Rare is a behavioral intervention that combines the CSNAT Pediatric Approach and the Respecting Choices® Next Steps ACP over 3 sessions. Sessions 1&2: CSNAT is an evidence-based process of family caregiver assessment and support in specialized medical (palliative) care. The CSNAT tool is structured around 16 categories of family caregiver support. With the goal to decrease caregiver burden, this process consists of 5 stages wherein a nurse or practitioner works with the caregiver to create a shared support plan for the child. Session 3: Respecting Choices® Next Steps- This advanced care planning (pACP) conversation engages families in a process for how to make future medical decisions consistent with their goals and values. The interview is structured in 6 stages to achieve 2 main goals: to facilitate conversations with the family about their child's medical condition, history, fears, values, beliefs, and hopes; and to set the stage for the family's future healthcare decisions.

Behavioral: FAmily CEntered (FACE) pACP Intervention
The (approximately) weekly 3-session FACE-Rare intervention of approximately 45-60 minutes each is comprised of the CSNAT approach [Sessions 1 & 2] and Respecting Choices [Session 3].
Other Names:
  • FACE-Rare Intervention
  • No Intervention: Treatment-as-Usual (TAU) Control

    To minimize the burden to families, we have chosen a Treatment-as-Usual (TAU) comparison condition, where patients will receive their normal standard of care. Both study arms will receive palliative (specialized medical) care information at enrollment and complete questionnaires before and after the intervention or TAU period. Current practice for minors with life-limiting illnesses is to defer initial discussions of advanced care planning (pACP) until a medical crisis, so this is what the TAU control arm condition will consist of.

    Outcome Measures

    Primary Outcome Measures

    1. Beck Anxiety Inventory [Change from Baseline Anxiety at 3 Months Post-Enrollment]

      Quality of life: emotional health. 21 items. Higher scores mean more depressive symptoms. Total score will be used in analysis. Scores range from 0-63.

    2. Functional Assessment of Chronic Illness Therapy (FACIT)- Spiritual Well-Being Scale, version 4 [Change from Baseline Spiritual Well-Being at 3 Months Post-Enrollment]

      Quality of life: spiritual (meaning/purpose, peace). Is culturally sensitive to those with non-theistic beliefs. 23 items. Total Score will be used in analysis. Higher scores mean higher spirituality. Scores range from 0-115.

    3. Advance Care Document for Children with Rare Diseases [Change from Baseline ACP Documentation at 12 weejs Post-Enrollment]

      Advanced Care Planning (ACP) Documentation in Electronic Health Records (EHR) & Decisional preferences. Score will be present in EHR or absent from EHR. Evidence of any advance care document (yes/no) will count.

    4. Initiation of Palliative Care Consultations [Change from Baseline Frequency at 12 weejs Post-Enrollment]

      Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Score will be present in EHR or absent from EHR. Evidence of consultation with the Palliative Care Team (yes/no) will count.

    5. Days in Palliative Care Prior to Death [12 weeks Post-Enrollment]

      Score is number of days patient was enrolled in a palliative care program in the 30 days prior to death. Applicable only to patients who have deceased since study enrollment. Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Minimum value is 0 with no maximum. Higher score indicates higher level of healthcare utilization.

    6. Hospitalizations [Change from Baseline Frequency at 12 weeks Post-Enrollment]

      Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Score is recorded number of inpatient hospital admissions for clinical treatment. Minimum value is 0 with no maximum. Higher score indicates higher level of healthcare utilization.

    7. Emergency Department (ED) Visits [Change from Baseline Frequency at 12 weeks Post-Enrollment]

      Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Score is reported number of ED visits. Minimum value is 0 with no maximum. Higher score indicates higher level of healthcare utilization.

    8. Intensive Care Unit (ICU) Use [Change from Baseline Frequency at 12 weeks Post-Enrollment]

      Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Score is number of times the patient was admitted to the ICU (including the NICU and PICU). Minimum value is 0 with no maximum. Higher score indicates higher level of healthcare utilization.

    9. Surgeries [Change from Baseline Frequency at 12 weeks Post-Enrollment]

      Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review. Score is number of surgical procedures the patient has undergone. Minimum value is 0 with no maximum. Higher score indicates higher level of healthcare utilization.

    10. Place of Death [12 weeks Post-Enrollment]

      Location where the patient was pronounced dead, as reported in their EMR. Applicable only to patients who have deceased since study enrollment. Categories are Inpatient hospice setting, Home with hospice, Home without hospice, Hospital ICU, Hospital-Not ICU, Other, or Unknown. Used to standardize child healthcare utilization from data abstraction based on retrospective medical chart review.

    Secondary Outcome Measures

    1. Brief-Multidimensional Measure of Religion and Spirituality [Change from Baseline Religiousness/Spirituality at 12 weeks Post-Enrollment]

      Religious Coping: 5 items from our previous research: attend religious services, feel God's presence, pray privately, identify as religious, identify as spiritual. 5 items scored on 5-point likert-scale. Range of scores from 0-25. Higher scores indicate higher levels of religiousness/spirituality.

    2. Family Appraisal of Caregiving Questionnaire for Palliative Care [Change from Baseline Appraisal of Caregiving at 12 weeks Post-Enrollment]

      Caregiver appraisal: caregiver strain, positive caregiving appraisals, caregiver distress, family well-being in past two weeks. 25 items. 5 point Likert scale. Scores range from 0-125. Two scales are reversed scored to yield higher total score equals higher positive family appraisal of caregiving. We will also examine subscale scores--higher scores indicate higher level of that construct.

    Other Outcome Measures

    1. Satisfaction Questionnaire [Up to 5 Weeks Post-Baseline]

      Study-specific process measure to assess adverse events and benefit/burden of participation. 12 items. Possible scores range from 13-65, where higher scores indicate greater satisfaction with study participation.

    2. Hickman Role Stress Decisional Burden Scale [Up to 5 Weeks Post-Enrollment]

      Visual analogue scale 0-100. "How stressful is it for you to make medical decisions for your child?" 1 item. Higher score means more stress, lower scores mean less stress.

    3. Quality of Communication Questionnaire [Up to 5 Weeks Post-Baseline]

      Process measure to assess how participating families rated the interviewer's quality of communication and overall discussion. 5 items. 5 point Likert scale. Possible scores range from 0-25, where higher scores indicate better perception of communication.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Child inclusion criteria are

    1. ≥1.0 years and <18.0 years at enrollment;e

    2. unable to participate in end-of-life care decision-making;

    3. have a rare disease as operationally defined (See Human Subjects);

    4. not under a Do Not Resuscitate Order or Allow a Natural Death Order; and

    5. not in the Intensive Care Unit.

    Family caregiver inclusion criteria are:
    1. ≥ 18.0 years at enrollment;

    2. legal guardian of child and child's caregiver;

    3. can speak and understand English; and

    4. not known to be developmentally delayed.

    Exclusion Criteria:

    (1) Family caregiver is actively homicidal, suicidal, or psychotic at the time of enrollment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Children's National Hospital Washington District of Columbia United States 20010

    Sponsors and Collaborators

    • Children's National Research Institute
    • Respecting Choices
    • National Institutes of Health (NIH)
    • National Institute of Nursing Research (NINR)

    Investigators

    • Principal Investigator: Maureen E Lyon, PhD, Children's National Research Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Maureen Lyon, Dr. Maureen Lyon, Ph.D, ABPP, Children's National Research Institute
    ClinicalTrials.gov Identifier:
    NCT04855734
    Other Study ID Numbers:
    • 00008808
    • 1R21NR019340-01
    First Posted:
    Apr 22, 2021
    Last Update Posted:
    Aug 3, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Maureen Lyon, Dr. Maureen Lyon, Ph.D, ABPP, Children's National Research Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 3, 2021